Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 5/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760933 | 0.93 | FAAH (0.54) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1760941 | 0.88 | FAAH (0.45) | FAAHALDH1A1 | |
| SCHEMBL2932276 | 0.88 | CYP2D6 (0.41) | CYP2D6TSHRUSP2CYP1A2CYP2C19 | |
| SCHEMBL1760990 | 0.88 | PKM (0.41) | FAAH | |
| SCHEMBL1760928 | 0.87 | FAAH (0.43) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1760930 | 0.87 | FAAH (0.45) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1761042 | 0.86 | PPARD (0.43) | FAAHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1760859 | 0.85 | FAAH (0.50) | CYP2D6FAAHUSP2CYP2C19ALDH1A1 | |
| SCHEMBL1760935 | 0.85 | FAAH (0.43) | FAAH | |
| SCHEMBL1761028 | 0.85 | FAAH (0.47) | FAAHADORA2AADORA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | CYP2D6 1665/4885TSHR 128/4885FAAH 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.